You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國生物製藥(01177.HK)治療骨關節炎藥物“鹽酸氨基葡萄糖片”通過仿製藥一致性評價
格隆匯 01-21 12:12

格隆匯1月21日丨中國生物製藥(01177.HK)公告,公司附屬公司江蘇正大清江製藥有限公司的治療骨關節炎藥物“鹽酸氨基葡萄糖片”(商品名稱:九力)獲得中國國家藥品監督管理局批准通過仿製藥質量和療效一致性評價,該產品成為國內首個通過一致性評價的鹽酸氨基葡萄糖製劑(750mg╱片)。

氨基葡萄糖是骨關節炎對因治療的首選藥物,其主要作用機制為:提供內源性氨基葡萄糖,促進關節軟骨的修復和重建;及通過抑制多種炎症介質,達到緩解和消除骨性關節炎的疼痛、腫脹等症狀。氨基葡萄糖已被國內外多部臨牀治療指南推薦使用。

骨關節炎患者服用氨基葡萄糖需足量足療程。該集團研製的鹽酸氨基葡萄糖片獲通過一致性評價,使骨關節炎患者能夠安心服用療效確切、價格更為經濟的國產藥物,社會效益明顯。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account